On Tuesday, Gilead Sciences, Inc (NASDAQ: GILD) opened higher 0.98% from the last session, before settling in for the closing price of $109.95. Price fluctuations for GILD have ranged from $62.07 to $111.03 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 5.32% annually for the last half of the decade. Company’s average yearly earnings per share was noted 71.67% at the time writing. With a float of $1.24 billion, this company’s outstanding shares have now reached $1.25 billion.
In an organization with 18000 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 57.7%, operating margin of 28.97%, and the pretax margin is 2.4%.
Gilead Sciences, Inc (GILD) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Gilead Sciences, Inc is 0.20%, while institutional ownership is 86.54%. The most recent insider transaction that took place on Feb 18 ’25, was worth 14,999,996. In this transaction 10% Owner of this company bought 1,363,636 shares at a rate of $11.00, taking the stock ownership to the 31,424,760 shares. Before that another transaction happened on Feb 18 ’25, when Company’s Chief Financial Officer sold 2,500 for $104.09, making the entire transaction worth $260,225. This insider now owns 169,061 shares in total.
Gilead Sciences, Inc (GILD) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 71.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.09% during the next five years compared to -38.21% drop over the previous five years of trading.
Gilead Sciences, Inc (NASDAQ: GILD) Trading Performance Indicators
Check out the current performance indicators for Gilead Sciences, Inc (GILD). In the past quarter, the stock posted a quick ratio of 1.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.82. Likewise, its price to free cash flow for the trailing twelve months is 14.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.37, a number that is poised to hit 1.77 in the next quarter and is forecasted to reach 8.36 in one year’s time.
Technical Analysis of Gilead Sciences, Inc (GILD)
Let’s dig in a bit further. During the last 5-days, its volume was 8.75 million. That was better than the volume of 7.54 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 95.77%. Additionally, its Average True Range was 2.40.
During the past 100 days, Gilead Sciences, Inc’s (GILD) raw stochastic average was set at 96.71%, which indicates a significant increase from 94.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.00% in the past 14 days, which was higher than the 24.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $95.59, while its 200-day Moving Average is $82.41. However, in the short run, Gilead Sciences, Inc’s stock first resistance to watch stands at $112.20. Second resistance stands at $113.36. The third major resistance level sits at $114.74. If the price goes on to break the first support level at $109.66, it is likely to go to the next support level at $108.28. Assuming the price breaks the second support level, the third support level stands at $107.12.
Gilead Sciences, Inc (NASDAQ: GILD) Key Stats
There are currently 1,246,266K shares outstanding in the company with a market cap of 138.37 billion. Presently, the company’s annual sales total 28,754 M according to its annual income of 480,000 K. Last quarter, the company’s sales amounted to 7,569 M and its income totaled 1,783 M.
